antithrombotic activity

TRIA-662 (Nicotinamide Chloromethylate) 是内源性代谢产物的一种。

Trombodipine (PCA-4230) 是一种血小板聚集抑制剂，具有抗血栓活性，对单核细胞增生李斯特菌具有保护作用。

Linotroban（CL-871502） 是一种有效的选择性血栓素（TXA2）受体拮抗剂，具有抗血栓活性。

Fidexaban (CI1031) 是一种新型、强效、选择性和口服活性 Xa 因子抑制剂，在多种测定中均显示出抗血栓活性。

LY 517717 是一种具有口服活性的凝血因子 Xa 抑制剂，具有抗血栓活性，可用于研究静脉血栓栓塞（VTE）。

BMS-986141(UDM-003183) 是一种具有口服活性的选择性和高效性的凝血酶受体蛋白酶激活受体-4 (protease-activated receptor-4 (PAR-4)) 拮抗剂，其 IC50 值为 0.4 nM。BMS-98614 表现出显著的抗血栓作用。

Iliparcil 是一种具有口服活性的抗血栓化合物。

BMS-593214 是一种选择性活性位点定向因子 VIIa 抑制剂，也是 VIIa 激活底物 FX 的非竞争性抑制剂，具有抗血栓形成和抗出血活性。BMS-593214 可用于研究电诱导颈动脉血栓形成 (AT)和线诱导腔静脉血栓形成 (VT)。

Nothofagin 具有抗氧化和抗血栓活性，它通过抑制高渗透性、CAMs 的表达以及白细胞的粘附和迁移具有抗炎活性，从而支持其作为血管炎症性疾病的治疗作用。

Viquidil hydrochloride (Quinotoxine hydrochloride) 是奎尼丁的同分异构体，是一种脑血管扩张剂，具有抗血栓作用。

Razaxaban hydrochloride is a highly potent, selective and orally active inhibitor of factor Xa(Ki of 0.19 nM),has strongly antithrombotic activity.

RWJ-445167 is a thrombin and factor Xa dual inhibitor(Ki of 4.0 nM and 230 nM, respectively), with potent antithrombotic activity.

Odiparcil is an orally active beta-d-thioxyloside analog. Odiparcil is an indirect thrombin inhibitor that exerts its anticoagulant effect through activation of antithrombin II (heparin cofactor II). It also has an antithrombotic activity associated with a reduced risk of adverse bleeding events.

Tecarfarin sodium is a novel orally active non-competitive vitamin K epoxide reductase antagonist. Tecarfarin sodium has the antithrombotic activity.

Tecarfarin (ATI-5923) 是一种具有口服活性和有效性的维生素 K 环氧化物还原酶 (VKOR) 拮抗剂和大麻素-1受体反向激动剂，具有抗血栓形成活性，可减轻小鼠的腹痛并增加肠道转运。

Thrombin Inhibitor 2 is a small molecule direct thrombin inhibitor. Thrombin Inhibitor 2 has antithrombotic activity.

LK-732, 作为一种凝血酶抑制剂，具备抗血栓形成能力。该化合物在 hypercoagulability 模型中显示出剂量依赖的抑制作用，其 IC50 值达到 1.3 mg kg。此外，LK-732 还广泛应用于心脑血管领域的研究。

Diaplasinin (PAI-749) 是一种高效性的纤溶酶原激活剂抑制剂-1 (PAI-1) 抑制剂，具有抗血栓活性，可用于研究心血管疾病。

Ilexoside D has ant-allergic, and anti-coagulant activities, it shows anti-tissue factor activity as well as the antithrombotic activity.

Nafazatrom is a pyrazolinone derivative and lipoxygenase inhibitor that increases endogenous prostacyclin (PGI2) and has experimental anticancer activity. Nafazatrom is also an antithrombotic drug that increases prostacyclin levels and reduces the inciden

Potent P2Y12 antagonist (IC50 = 17 nM). Displays antiplatelet and antithrombotic activity in vivo. Orally available. Boldron et al (2014) N-[6-(4-butanoyl-5-methyl-1H-pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1H-indole-3-carboxamide (SAR216471), a novel intravenous and oral, reversible, and directly acting P2Y12 antagonist. J.Med.Chem. 57 7293 PMID:25075638

Fondaparinux sodium (SR-90107A) 是抗凝血酶依赖性的 factor Xa 抑制剂。

Saponin C from Liriope muscari 可从百合科植物 Liriope muscari中提取,具有抗血栓活性,可诱导自噬。

GPVI antagonist 3 (Compound 2) is a potential antagonist that shows promising antiplatelet activity by selectively inhibiting the interaction between the Glycoprotein VI (GPVI) receptor and its ligands. It demonstrates potent inhibitory effects, with IC50 values of 1.01 μM for collagen, 1.92 μM for CRP, 7.24 μM for convulxin, and 51.74 μM for thrombin. GPVI is a major collagen receptor on platelets, making it an ideal target for safe and effective antithrombotic treatment. Therefore, GPVI antagonist 3 holds potential as a novel antiplatelet agent [1].